Burjeel to locally manufacture CAR-T cell therapies in new partnership

The initiative aims to offer therapies at costs up to 90% lower.

Burjeel Holdings has partnered with US-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs.

The non-profit will provide the group with technology, materials, training, and lentiviral vectors to support local manufacturing and clinical development.

The programme’s first phase will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future.